Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician
The pharmacologic treatment of diabetic kidney disease (DKD) has typically involved treatment of associated risk factors such as blood glucose, blood pressure, and the use of medications that act on the renin-angiotensin-aldosterone system. Recently, a variety of glucose-lowering medications have been investigated to assess their potential for improved renal outcomes in patients with type 2 diabetes mellitus and with/without established DKD. Several of these medications have been shown to improve renal outcomes in patients with type 2 diabetes mellitus. In short, this presentation seeks to provide insight into the results of these clinical trials and how the selected medications can be used to individualize therapy as recommended in updated guidelines issued by the American Diabetes Association and the American Association of Clinical Endocrinologists/American College of Endocrinology.
At the end of the activity, participants will be able to:
- Identify risks of kidney disease and its consequences in patients with T2DM.
- Appropriately screen for the presence of CKD in patient with T2DM.
- Initiate evidence-based therapy to slow the progression of kidney disease in patients with T2DM and CKD.
- Become familiar with the mineralocorticoid receptor antagonist and endothelin receptor antagonist under late-phase investigation.
Christine Kessler, MN, CNS, ANP-C, BC-ADM, CDTC, FAANP
Christine Kessler is an award-winning nurse practitioner, national/international speaker, prolific author, and clinical consultant specializing in Endocrinology and Metabolic Medicine. During her years practice she has held diverse roles in management, research, academia, and clinical practice; the latter as a critical care clinical specialist, an acute care nurse practitioner (as an Intensivist) and an adult nurse practitioner. After 15 years as the senior nurse practitioner at the Walter Reed National Military Medical Center, Department of Endocrinology and Metabolic Medicine, Christine now focuses on providing diabetes and weight loss management. In addition to the general endocrine clinical and home services to an under-served population in rural Virginia. Also, Christine has received several clinical practice awards. Currently, Christine co-chairs the popular, national Metabolic & Endocrine Disease Summit and is a Fellow of the American Association of Nurse Practitioners.
Continuing education credits are provided by Primary Care Education Consortium (PCEC).
PCEC designates this enduring material for 1.00 Prescribed credit(s) by the American Academy of Family Physicians. Other clinicians may receive CE credit from the respective organizations.
Course and educational credits are provided by Primary Care Education Consortium (PCEC) and is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Course Expiration Date: December 31, 2020